These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27925353)

  • 21. Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study.
    Bañares J; Manzano-Nuñez R; Prió A; Rivera-Esteban J; Camps-Relats L; Villarejo A; Ruiz-Ortega L; Pons M; Ciudin A; Salcedo MT; Vargas V; Genescà J; Pericàs JM
    Front Endocrinol (Lausanne); 2022; 13():945626. PubMed ID: 36093073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial).
    Sumida Y; Murotani K; Saito M; Tamasawa A; Osonoi Y; Yoneda M; Osonoi T
    Hepatol Res; 2019 Jan; 49(1):64-71. PubMed ID: 30051943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB-4 index in metabolic-associated fatty liver disease.
    Mino M; Kakazu E; Sano A; Katsuyama H; Hakoshima M; Yanai H; Aoki Y; Imamura M; Yamazoe T; Mori T; Yoshio S; Inoue J; Masamune A; Kanto T
    Hepatol Res; 2023 Jul; 53(7):618-628. PubMed ID: 36905232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data.
    Arai T; Atsukawa M; Tsubota A; Mikami S; Ono H; Kawano T; Yoshida Y; Tanabe T; Okubo T; Hayama K; Nakagawa-Iwashita A; Itokawa N; Kondo C; Kaneko K; Emoto N; Nagao M; Inagaki K; Fukuda I; Sugihara H; Iwakiri K
    Ther Adv Endocrinol Metab; 2021; 12():20420188211000243. PubMed ID: 33815743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor.
    Sugiyama S; Jinnouchi H; Hieshima K; Kurinami N; Jinnouchi K
    Cureus; 2020 Feb; 12(2):e7110. PubMed ID: 32175210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study.
    Chou OHI; Chauhan VK; Chung CTS; Lu L; Lee TTL; Ng ZMW; Wang KKW; Lee S; Liu H; Pang RTK; Kaewdech A; Cheung BMY; Tse G; Zhou J
    Gastric Cancer; 2024 Jun; ():. PubMed ID: 38856768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
    Ohki T; Isogawa A; Toda N; Tagawa K
    Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study).
    Ishii H; Nakajima H; Kamei N; Niiya T; Hiyoshi T; Hiramori Y; Ohtsu S; Noto T; Shimono D
    Diabetes Ther; 2020 Dec; 11(12):2959-2977. PubMed ID: 33057967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study.
    Akuta N; Kawamura Y; Fujiyama S; Saito S; Muraishi N; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kumada H
    Hepatol Commun; 2022 Sep; 6(9):2286-2297. PubMed ID: 35581956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials.
    Jin Z; Yuan Y; Zheng C; Liu S; Weng H
    J Diabetes Complications; 2023 Aug; 37(8):108558. PubMed ID: 37499274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis.
    Chung MC; Hsu HT; Chang CH; Hung PH; Hsiao PJ; Wu LY; Wu MJ; Shieh JJ; Chung CJ
    Sci Rep; 2022 Jun; 12(1):10147. PubMed ID: 35710921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.
    Sumida Y; Seko Y; Yoneda M;
    Hepatol Res; 2017 Mar; 47(4):266-280. PubMed ID: 28019064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis.
    Mui JV; Zhou J; Lee S; Leung KSK; Lee TTL; Chou OHI; Tsang SL; Wai AKC; Liu T; Wong WT; Chang C; Tse G; Zhang Q
    Front Cardiovasc Med; 2021; 8():747620. PubMed ID: 34746262
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus.
    Akuta N; Kawamura Y; Watanabe C; Nishimura A; Okubo M; Mori Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Hepatol Res; 2019 May; 49(5):531-539. PubMed ID: 30577089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene.
    Yang JY; Wang T; Pate V; Buse JB; Stürmer T
    BMJ Open Diabetes Res Care; 2020 Jan; 8(1):. PubMed ID: 31958306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy of sodium-glucose cotransporter 2 inhibitor therapy in preventing atrial fibrillation recurrence after catheter ablation in type 2 diabetes mellitus patients.
    Liu HT; Wo HT; Chang PC; Lee HL; Wen MS; Chou CC
    Heliyon; 2023 Jun; 9(6):e16835. PubMed ID: 37332966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.
    Arase Y; Kawamura Y; Seko Y; Kobayashi M; Suzuki F; Suzuki Y; Akuta N; Kobayashi M; Sezaki H; Saito S; Hosaka T; Ikeda K; Kumada H; Ohmoto-Sekine Y; Hsieh SD; Amakawa K; Ogawa K; Matsumoto N; Iwao A; Tsuji H; Hara S; Mori Y; Okubo M; Sone H; Kobayashi T
    Hepatol Res; 2013 Nov; 43(11):1163-8. PubMed ID: 23489256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease.
    Chen L; Zhang X; Zhang L; Zheng D
    Diabetes Metab Syndr Obes; 2020; 13():3507-3518. PubMed ID: 33116702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.